Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Various embodiments relate to a device for simultaneous consumption of a fluid and a frozen substance. in some embodiments, the device can include a handle assembly and a variable-volume chamber configured to store at least a portion of the fluid substance, the variable-volume chamber removably connected to the handle assembly. A cover can be removably coupled with the handle assembly. The cover can have an open end and a closed end and can at least partially define a mold cavity for molding the freezable substance.

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (ID-UA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: Various embodiments relate to a device for simultaneous consumption of a fluid and a frozen substance. In some embodiments, the device can include a squeezable chamber configured to store at least a portion of the fluid substance. A flange can be connected at a first end to the squeezable chamber. The flange can define a cavity in fluid communication with an interior of the squeezable chamber such that, when the squeezable chamber is squeezed by a user, the fluid substance is driven from the squeezable chamber and through at least a portion of the cavity defined by the flange. In some embodiments, one or more optical emitters can be coupled with the device.

Abstract: An apparatus for consuming a freezable substance is disclosed. The apparatus can comprise a squeezable chamber configured to store a liquid. The apparatus can comprise a flange coupled to or formed with the squeezable chamber, the flange sized and shaped to support the freezable substance. The apparatus can comprise a liquid pathway from the squeezable chamber through the flange to deliver the liquid to the freezable substance.

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothclial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment-to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: The invention relates to a process for preparing methylenediphenyldiamine (MDA) by reacting formaldehyde and aniline in the presence of an acidic catalyst, wherein the oxygen content in the process for preparing MDA is <10 000 ppm, based on all compounds present in the process. The invention further relates to the phosgenation of MDA to methylenediphenyl diisocyanate (MDI).

Abstract: The invention relates to a process for preparing methylenediphenyldiamine (MDA) by reacting formaldehyde and aniline in the presence of an acidic catalyst, wherein the oxygen content in the process for preparing MDA is <10 000 ppm, based on all compounds present in the process. The invention further relates to the phosgenation of MDA to methylenediphenyl diisocyanate (MDI).

Abstract: A transportable cooking container with a fastener joint on the bottom wall of the container. An anchor post consisting of a vertical component with an auger at one end. An anchor post consisting of a horizontal component attached to the vertical component spaced ? up the total length of the vertical component from the auger end of the vertical component. The non-auger end of the vertical component can be inserted into the fastener joint on the bottom wall of the cooking container, which fastener joint can be manually moved between an opened position, opening the clasp allowing for insertion of the vertical component, and a closed position, securing the cooking container to the vertical component of the anchor post.